Levemir and Blindness unilateral - a phase IV clinical study of FDA data

Summary:

Blindness unilateral is reported as a side effect among people who take Levemir (insulin detemir recombinant), especially for people who are female, 60+ old, also take Humalog, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Blindness unilateral when taking Levemir. It is created by eHealthMe based on reports of 13,520 people who have side effects when taking Levemir from the FDA, and is updated regularly.

What is Levemir?

Levemir has active ingredients of insulin detemir recombinant. It is often used in diabetes. eHealthMe is studying from 13,850 Levemir users. Check the latest studies of Levemir.

What is Blindness unilateral?

Blindness unilateral is found to be associated with 877 drugs and 979 conditions by eHealthMe. Check the latest studies of Blindness unilateral.

On Jul, 15, 2026

13,520 people reported to have side effects when taking Levemir.
Among them, 17 people (0.13%) have Blindness unilateral.

Could Levemir cause Blindness unilateral?

Among these 17 people:

What is the gender of people who have Blindness unilateral when taking Levemir? *

female: 80 %
male: 20 %

What is the age of people who have Blindness unilateral when taking Levemir? *

What are other drugs people take besides Levemir? *

What are other side effects people have besides Blindness unilateral? *

Visual Acuity Reduced (reduced clearness of vision): 5 people, 29.41%
Vision Blurred: 4 people, 23.53%
Blood Glucose Increased: 4 people, 23.53%
Intraocular Pressure Increased: 3 people, 17.65%
Scurvy (a disease caused by deficiency of vitamin c, characterized by spongy and bleeding gums, bleeding under the skin, and extreme weakness): 2 people, 11.76%
Drug Ineffective: 2 people, 11.76%
Eye Haemorrhage (bleeding in the eye): 2 people, 11.76%
Myelitis (infection or the inflammation of white matter or gray matter of spinal cord which is a part of central nervous system): 2 people, 11.76%
Glaucoma (increased fluid pressure in the eye with vision loss): 2 people, 11.76%
Rickets (softening of bones): 2 people, 11.76%

What are the existing conditions these people have? *

Retinal Vessel Occlusion (a blockage in one of the small arteries): 1 person, 5.88%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 5.88%
Lung Disorder (lung disease): 1 person, 5.88%
Intraocular Pressure Increased: 1 person, 5.88%
Insulin-Requiring Type Ii Diabetes Mellitus: 1 person, 5.88%
High Blood Cholesterol: 1 person, 5.88%
Hepatitis C: 1 person, 5.88%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 5.88%
Eye Haemorrhage (bleeding in the eye): 1 person, 5.88%
Dyslipidaemia (abnormal amount of lipids): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Levemir and have Blindness unilateral?

- Check whether Blindness unilateral is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Levemir:

Levemir (13,850 reports)

Browse all side effects of Levemir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness unilateral:

Blindness unilateral (877 drugs)

Browse all the conditions that are associated with Blindness unilateral:

Blindness unilateral (979 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin detemir recombinant (the active ingredients of Levemir) and Levemir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.